Travel Tip
 Conf TL
 RF Club
 FM Alert
 FM Approval
News Super Search
Posting Date From:
Posting Date To:
IR Press Release:


Purulia Express: লালপাহাড়ীর দ‍্যাশে যাবি? চিন্তা কিসের লো? বিকাল বেলা হাওড়া থেকে পুরুল্যা এক্সপেরেস পাবি। - Dip

Full Site Search
  Full Site Search  
Tue Oct 20 06:39:06 IST
Advanced Search
<<prev entry    next entry>>
News Entry# 419039
Sep 20 (16:32) DCGI approves commercial launch of Tata Group’s low-cost COVID-19 test 'Feluda' (

News Entry# 419039  Blog Entry# 4720919   
  Past Edits
This is a new feature showing past edits to this News Post.
Last Updated : Sep 20, 2020 12:15 PM IST |
The COVID-19 test developed by Tata Group and CSIR-IGIB reportedly achieves accuracy levels of the traditional RT-PCR tests with quicker turnaround time.
The Drugs Controller General of India (DCGI) has approved the commercial launch of 'Feluda', a COVID-19 test developed by the Tata Group and CSIR-IGIB (Council of Scientific and Industrial Research-Institute of Genomics and Integrative Biology).
test uses an indigenously-developed CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology for detection of SARS-CoV-2’s genomic sequence. CRISPR, a technology developed by CSIR-IGIB (Institute of Genomics and Integrative Biology), is a genome editing technology used to diagnose diseases.
This CRISPR test reportedly achieves accuracy levels of the traditional RT-PCR tests with quicker turnaround time. The test uses less expensive equipment and is easier to use.
"The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR (Indian Council of Medical Research) guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus," CSIR’s statement said.
This is the world's first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the novel coronavirus, which causes COVID-19.
News agency PTI quoted Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd. say saying that the “Approval for the Tata CRISPR test for COVID-19 will give a boost to the country's efforts in fighting the global pandemic.”
“The commercialisation of Tata CRISPR test reflects the tremendous R&D talent in the country which can collaborate to transform India's contributions to the global healthcare and scientific research world," he said.
According to PTI, CSIR-IGIB Director Anurag Agrawal said that the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.

(With inputs from PTI)
Scroll to Top
Scroll to Bottom
Go to Mobile site
Important Note: This website NEVER solicits for Money or Donations. Please beware of anyone requesting/demanding money on behalf of IRI. Thanks.
Disclaimer: This website has NO affiliation with the Government-run site of Indian Railways. This site does NOT claim 100% accuracy of fast-changing Rail Information. YOU are responsible for independently confirming the validity of information through other sources.
India Rail Info Privacy Policy